Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04781972
PHASE4

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.

Key Details

Gender

All

Age Range

6 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-07-27

Completion Date

2029-04-30

Last Updated

2025-10-16

Healthy Volunteers

No

Interventions

DRUG

Methylphenidate

single dose of 10 mg or 15 mg

DRUG

Placebo

Matching placebo

Locations (1)

Johns Hopkins School of Medicine

Baltimore, Maryland, United States